ADMIRE-ICD
AdreView™ Myocardial Imaging for Risk Evaluation – A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35%
- Stadium
- klaar
- Middel
- Jodium-123 meta-iodobenzylguanidine (MIBG)
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 1 januari 2016
- Last Patient In
- -
- Last Patient Last Visit
- -
Contact Bestuur
